- Home
- ONEW vs ACRV Comparison
ONEW vs ACRV Comparison
Compare ONEW & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONEW
- ACRV
- Stock Information
- Founded
- ONEW 2014
- ACRV 2018
- Country
- ONEW United States
- ACRV United States
- Employees
- ONEW N/A
- ACRV N/A
- Industry
- ONEW Auto & Home Supply Stores
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ONEW Consumer Discretionary
- ACRV Health Care
- Exchange
- ONEW Nasdaq
- ACRV Nasdaq
- Market Cap
- ONEW 292.5M
- ACRV 247.8M
- IPO Year
- ONEW 2020
- ACRV 2022
- Fundamental
- Price
- ONEW $20.00
- ACRV $6.96
- Analyst Decision
- ONEW Buy
- ACRV Strong Buy
- Analyst Count
- ONEW 5
- ACRV 5
- Target Price
- ONEW $30.00
- ACRV $22.40
- AVG Volume (30 Days)
- ONEW 79.6K
- ACRV 47.9K
- Earning Date
- ONEW 11-14-2024
- ACRV 11-13-2024
- Dividend Yield
- ONEW N/A
- ACRV N/A
- EPS Growth
- ONEW N/A
- ACRV N/A
- EPS
- ONEW N/A
- ACRV N/A
- Revenue
- ONEW $1,772,630,000.00
- ACRV N/A
- Revenue This Year
- ONEW N/A
- ACRV N/A
- Revenue Next Year
- ONEW $4.21
- ACRV N/A
- P/E Ratio
- ONEW N/A
- ACRV N/A
- Revenue Growth
- ONEW N/A
- ACRV N/A
- 52 Week Low
- ONEW $19.73
- ACRV $3.19
- 52 Week High
- ONEW $35.86
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- ONEW 36.07
- ACRV 34.20
- Support Level
- ONEW $23.38
- ACRV $7.69
- Resistance Level
- ONEW $25.72
- ACRV $8.54
- Average True Range (ATR)
- ONEW 1.23
- ACRV 0.44
- MACD
- ONEW -0.27
- ACRV -0.10
- Stochastic Oscillator
- ONEW 3.83
- ACRV 3.78
About ONEW OneWater Marine Inc.
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segment- Dealerships and Distribution. Its dealer groups are located throughout the Southeast, Gulf Coast, Mid-Atlantic, and Northeast. The company's revenue profile is comprised of new boat sales, pre-owned boat sales, finance and insurance products, repair and maintenance services, and parts and accessories. Majority of revenue is generated from sale of new boats.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.